Latest News

Date Title Topic
15 Jun 2018 FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy Gynaecologic malignancies - Cancer Immunology and Immunotherapy
13 Jun 2018 ESMO Handbook of Interpreting Oncological Study Publications
13 Jun 2018 ASCO 2018: Exemestane Plus Ovarian Function Suppression Controls Distant Recurrences Over the Long Term in Premenopausal Women with HR-positive, HER-negative Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
11 Jun 2018 ASCO 2018: First-Line Atezolizumab Improves Survival in Advanced NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
30 May 2018 ESMO Translational Research Unit Visits
29 May 2018 NICE Issues Interventional Procedures Guidance on Low-Level Laser Therapy Palliative and supportive care
23 May 2018 New Clinical Practice Guidelines
29 May 2018 New Clinical Practice Guidelines
29 May 2018 New Clinical Practice Guidelines
28 May 2018 Patients with mUC and Low PD-L1 Expression May Have Decreased Survival When Treated with Pembrolizumab or Atezolizumab Genitourinary cancers - Cancer Immunology and Immunotherapy
25 May 2018 GDPR as of today: ESMO reinforces harmonious uptake of health research provisions
23 May 2018 No Evidence that FDA Breakthrough-Designated Anticancer Drugs Provide Improvements in Efficacy, Safety or Novelty Anticancer agents & Biologic therapy
24 May 2018 ESMO Emphasises Importance of Cancer on the Global Health Agenda at the 71st World Health Assembly [ESMO Press Release] Bioethics, legal and economic issues - Epidemiology/Etiology/Cancer Prevention
08 May 2018 FDA Expends Approval for CAR-T Therapy, Tisagenlecleucel Haematologic malignancies - Cancer Immunology and Immunotherapy
08 May 2018 Patient Guide on Survivorship Now Available in Croatian